The glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and now next-generation multi-agonists that include GLP-1 activity, are producing average weight reductions far larger than previously expected from drugs, reshaping clinical practice and how clinicians and patients think about obesity treatment
They also support insulin production and help control blood sugar, which can be especially helpful for people with type 2 diabetes
The impact of Wegovy on the Medicare population may not be as significant as the impact commercial payers have seen when choosing to cover Wegovy, given the concomitant prevalence of diabetes and overweight/obesity in Americans over age 65
The endocannabinoid system links gut microbiota to adipogenesis
Timing Matters: When to Address Skin Laxity One of the most important considerations is when to treat
Numerous studies have found that GLP-1 agonists can be effective for weight loss, blood sugar management, and heart health, especially when combined with diet and lifestyle changes